PAEDIATRIC DERMATOLOGY

Practice‐based differences in paediatric discoid lupus erythematosus

Commentary or Editorial available

Plain Language Summary available

Article first published online: 24 Jun 2019
DOI: 10.1111/bjd.17780

Comment on this article

Summary

Background

Children with discoid lupus erythematosus ( DLE ) are at risk for disfigurement and progression to systemic lupus erythematosus ( SLE ). Consensus is lacking regarding optimal care for children with DLE .

Objectives

The aim of this study was to compare practice patterns among paediatric dermatologists/rheumatologists treating paediatric DLE .

Methods

An online survey was sent to 292 paediatric rheumatologists in the Childhood Arthritis and Rheumatology Research Alliance and 200 paediatric dermatologists in the Pediatric Dermatology Research Alliance. Consensus was defined as ≥ 70% agreement.

Results

Survey response rates were 38% (76 of 200) for dermatology and 21% (60 of 292) for rheumatology. Both specialties agreed that screening labs should include complete blood counts with differential, urinalysis, complement levels, erythrocyte sedimentation rate, antinuclear antibody and other autoantibodies, hepatic function and renal function/electrolytes. Both specialties agreed that arthritis or nephritis should prompt intensified evaluation for SLE . No other patient features achieved consensus as disease‐modifying risk factors. Hydroxychloroquine was agreed upon as first‐line systemic therapy, but consensus was lacking for second‐ or third‐line treatment.

Conclusions

We found few areas of consensus and significant practice differences between paediatric dermatologists and rheumatologists treating DLE . Knowledge gaps include risk factors for SLE , optimal screening and treatment of refractory skin disease.

Read moreRead more (PDF)

Share this article

0

Favourite

Comments

If you want to submit a letter for publication rather than comment on an article please submit through Scholar One: https://mc.manuscriptcentral.com/bjd

There are no comments for this article yet.

Recent Tweets

@BrJDermatol

13 Nov 2019

Find out how changing immunosuppressive treatment practices have impacted SCC and BCC cancer risk in organ transplant recipients at https://t.co/wlvY9C1BnB #SCC #BCC #organtransplant #epidemiology https://t.co/tofI5FYhdu

@BrJDermatol

13 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: We are very excited to be planning the launch of a new open access journal, for which we are now looking for an Editor-in-Chief. Full details and information on how to apply for this role can be found here: https://t.co/42Fego0m99 @BrJDermatol @ced_wiley https://t.co/RAtLL76qpd

@BrJDermatol

13 Nov 2019

RT Dr Katie Farquhar @katiefarquhar: Very interesting article looking at skin cancer trends in transplant recipients from @BrJDermatol https://t.co/ia0PTvQCx9

@BrJDermatol

12 Nov 2019

Why has there been a significant reduction in the incidences of both SCC and BCC in organ transplant recipients over the past two decades? https://t.co/9LZepIh0V0 #SCC #BCC #organtransplant #epidemiology https://t.co/7mFJDPG3ch

@BrJDermatol

12 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: There is a need for more economic studies which look at the costs and effectiveness of two or more eczema treatments. These types of studies help inform how healthcare resources are used. https://t.co/jXK2mF2WQe @BrJDermatol @Wiley_Health @eczemasociety https://t.co/r90pWBEcRK

@BrJDermatol

11 Nov 2019

Join the discussion regarding the definition and clinical implications of palmoplantar pustulosis at https://t.co/rvMFifNM5l #psoriasis #commentary https://t.co/4BQRcTOq2S

Close